These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 17505923

  • 1. Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda.
    Stangl AL, Wamai N, Mermin J, Awor AC, Bunnell RE.
    AIDS Care; 2007 May; 19(5):626-36. PubMed ID: 17505923
    [Abstract] [Full Text] [Related]

  • 2. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

  • 3. Determinants of health-related quality of life in HIV-infected patients.
    Murri R, Fantoni M, Del Borgo C, Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi V, Bosco O, Wu AW.
    AIDS Care; 2003 Aug; 15(4):581-90. PubMed ID: 14509872
    [Abstract] [Full Text] [Related]

  • 4. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 5. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda.
    Bajunirwe F, Tisch DJ, King CH, Arts EJ, Debanne SM, Sethi AK.
    AIDS Care; 2009 Mar 01; 21(3):271-9. PubMed ID: 19280404
    [Abstract] [Full Text] [Related]

  • 6. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.
    Clin Infect Dis; 2008 Jan 15; 46(2):305-12. PubMed ID: 18171267
    [Abstract] [Full Text] [Related]

  • 7. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
    de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de Wolf F, Nieuwkerk PT.
    Clin Infect Dis; 2010 Jan 15; 50(2):255-63. PubMed ID: 20014949
    [Abstract] [Full Text] [Related]

  • 8. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 9. Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era.
    Saunders DS, Burgoyne RW.
    Int J STD AIDS; 2002 Oct 15; 13(10):683-90. PubMed ID: 12396538
    [Abstract] [Full Text] [Related]

  • 10. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S, Alary M.
    HIV Med; 2009 Nov 15; 10(10):640-6. PubMed ID: 19659945
    [Abstract] [Full Text] [Related]

  • 11. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.
    Clin Infect Dis; 2006 Jan 01; 42(1):136-44. PubMed ID: 16323104
    [Abstract] [Full Text] [Related]

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Jan 01; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 13. The impact of highly active antiretroviral therapy on activities of daily living in HIV-infected adults in South Africa.
    Kakinami L, de Bruyn G, Pronyk P, Mohapi L, Tshabangu N, Moshabela M, McIntyre J, Martinson NA.
    AIDS Behav; 2011 May 01; 15(4):823-31. PubMed ID: 20703794
    [Abstract] [Full Text] [Related]

  • 14. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V, Thiébaut R, Chêne G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaïed F, Leport C, Raffi F, ANRS CO8 (APROCO/COPILOTE) Study Group.
    HIV Med; 2007 Apr 01; 8(3):156-63. PubMed ID: 17461859
    [Abstract] [Full Text] [Related]

  • 15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 16. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.
    Antivir Ther; 2006 Jun 15; 11(1):63-72. PubMed ID: 16518961
    [Abstract] [Full Text] [Related]

  • 17. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B, MANIF 2000 Study Group.
    Antivir Ther; 2005 Jun 15; 10(1):53-61. PubMed ID: 15751763
    [Abstract] [Full Text] [Related]

  • 18. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection.
    Powers AE, Marden SF, McConnell R, Leidy NK, Campbell CM, Soeken KL, Barker C, Davey RT, Dybul MR.
    AIDS; 2006 Apr 04; 20(6):837-45. PubMed ID: 16549967
    [Abstract] [Full Text] [Related]

  • 19. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM, Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.
    Pediatrics; 2005 Feb 04; 115(2):e173-82. PubMed ID: 15629958
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.